While the maintenance of a Buy rating indicates continued confidence in Inozyme Pharma's potential, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the new target.